S
Stockadora

Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4753 Reports
🤖 AI Analyzed
Recent
📄 Page 273 of 397
Invivyd, Inc.
10-K March 5, 2026

Key Highlights

  • Lead candidate INV-123 advanced to pivotal Phase 3 clinical trials in Q4 2025 af...
  • Secured a key strategic collaboration agreement in Q3 2025, providing non-diluti...
  • Expanded pipeline by moving two new preclinical antibody candidates into IND-ena...
Read Analysis
🤖 AI Generated
Grove Collaborative Holdings, Inc.
10-K March 5, 2026

Key Highlights

  • Significantly narrowed net loss to $78 million (from $105 million) and Adjusted ...
  • Improved gross margin to 33.3% from 31.5% in the prior year, driven by a better ...
  • Expanded retail presence into 500 new store locations and successfully launched ...
Read Analysis
🤖 AI Generated
FLYEXCLUSIVE INC.
10-K March 5, 2026

Key Highlights

  • Operates a fractional aircraft ownership model, making private aviation accessib...
  • Strategic fleet changes are underway, including designating Gulfstream G-IV airc...
  • Future plans include Sale-Leaseback transactions in 2025 and an At-The-Market (A...
Read Analysis
🤖 AI Generated
Ardagh Metal Packaging S.A.
20-F March 5, 2026

Key Highlights

  • Global leader in sustainable beverage metal packaging with an extensive manufact...
  • Investing in significant capacity expansion, targeting a 10% increase by late 20...
  • Strong commitment to sustainability, aiming for 75% recycled content by 2030 and...
Read Analysis
🤖 AI Generated
Global Crossing Airlines Group Inc.
10-K March 5, 2026

Key Highlights

  • GlobalX reported $185 million in total revenue for 2025, marking a significant 4...
  • The company successfully expanded its fleet to 15 aircraft by year-end 2025 and ...
  • GlobalX secured two new multi-year ACMI contracts and launched dedicated cargo o...
Read Analysis
🤖 AI Generated
Bowman Consulting Group Ltd.
10-K March 5, 2026

Key Highlights

  • Revenue surged by approximately 25% year-over-year, exceeding $300 million, driv...
  • Net income significantly improved to roughly $25 million, reflecting enhanced op...
  • Maintains a solid financial foundation with over $50 million in cash and strong ...
Read Analysis
🤖 AI Generated
Mobile Infrastructure Corp
10-K March 5, 2026

Key Highlights

  • Achieved significant net income of $8.2 million in 2025, a turnaround from a $1....
  • Reported 5% revenue growth, reaching $125.7 million in 2025, driven by strategic...
  • Generated strong cash flow from operations of $28.5 million, providing robust li...
Read Analysis
🤖 AI Generated
GH Research PLC
20-F March 5, 2026

Key Highlights

  • GH Research PLC is a clinical-stage biopharmaceutical company developing novel p...
  • Its lead product, GH001 (inhaled 5-MeO-DMT), is in Phase 2b clinical trials for ...
  • The company held approximately $150 million in cash and cash equivalents as of D...
Read Analysis
🤖 AI Generated
Contineum Therapeutics, Inc.
10-K March 5, 2026

Key Highlights

  • Successfully completed patient enrollment for CTNM-001 Phase 2 clinical trial in...
  • CTNM-002 granted Orphan Drug Designation in Q1 2025, with an Investigational New...
  • Secured two new patents covering composition of matter for CTNM-001 and a novel ...
Read Analysis
🤖 AI Generated
A.K.A. BRANDS HOLDING CORP.
10-K March 5, 2026

Key Highlights

  • Achieved 12% net revenue growth to $685 million in FY2025, driven by strong cust...
  • Improved net loss from $35 million in FY2024 to $22 million in FY2025, demonstra...
  • Generated $30 million in positive cash flow from operations and maintained $65 m...
Read Analysis
🤖 AI Generated
ArriVent BioPharma, Inc.
10-K March 5, 2026

Key Highlights

  • Lead candidate Firmonertinib is in clinical development, targeting oncology or r...
  • Strategic partnerships established with Lepu Biopharma, Aarvik Pharmaceuticals I...
  • Classified as both a "Smaller Reporting Company" and an "Emerging Growth Company...
Read Analysis
🤖 AI Generated
BridgeBio Oncology Therapeutics, Inc.
10-K March 5, 2026

Key Highlights

  • Focuses on RAS-dependent cancers with three product candidates (BBO-8520, BBO-10...
  • Successfully completed a de-SPAC transaction in August 2025, becoming a public c...
  • Reported encouraging preliminary safety and early anti-tumor data for all three ...
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage